Information Provided By: 
Fly News Breaks for July 29, 2016
ALKS
Jul 29, 2016 | 05:40 EDT
Barclays analyst Jonathan Eckard views yesterday's post-earnings selloff in shares of Alkermes as "misplaced." The outlook for Vivitrol is "even brighter than before," Eckard tells investors in a research note. He attributes the share pullback to concern over the gross to net pressure on Vivitrol. The gross to net is poised to stabilize as it is likely nearing its peak, the analyst contends. He raised his price target for Alkermes to $66 from $65 and keeps an Overweight rating on the shares.
News For ALKS From the Last 2 Days
